Is Omada Health, Inc. (NASDAQ:OMDA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Omada Health, Inc. at current levels.
GLP-1 wrappers are the most misunderstood opportunity in digital health, and Omada is the cleanest pure-play.
Where OMDA is headed
By the second half of 2027, Omada should be running close to a $400M revenue rate, GAAP profitable, and sitting on a member base that has roughly doubled from today's 1.1M enrollees. The shape of the business is shifting under the surface in a way the tape has not caught up to. Cardiometabolic was always the wedge. The GLP-1 companion program, launched in 2024 to wrap Wegovy and Zepbound prescriptions with behavioral coaching, nutrition guidance, and side-effect management, is becoming the actual product. Employers and PBMs are buying it for one reason: GLP-1 spend now eats 8-12% of pharmacy budgets at large self-insured employers, and the discontinuation rate inside the first year sits north of 60%. Every patient who quits is a $15,000 annual drug spend that produced nothing. Omada's pitch reframes their entire commercial motion from 'health coaching vendor' to 'GLP-1 ROI insurance.'
Read the full Compass Direction on OMDA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $16.52).
See the full OMDA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Omada Health, Inc. (NASDAQ:OMDA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Omada Health, Inc. at current levels. GLP-1 wrappers are the most misunderstood opportunity in digital health, and Omada is the cleanest pure-play.
What is OMDA's Compass Score?
Omada Health, Inc. scores 75/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for OMDA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the OMDA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.